Summary. The very low density lipoprotein (VLDL) fraction was isolated from 11 normolipidaemic Type i (insulindependent) diabetic patients in good to fair glycaemic control and from 11 age-, sex-and race-matched, non-diabetic, control subjects. The rate of receptor-mediated degradation by human endothelial cells was significantly greater (p < 0.02) for the total VLDL fraction isolated from diabetic patients compared to control subjects and averaged 1008 + 300 and 717+150 ng.mg cell protein-'.16 h 1, respectively. The total VLDL fraction was separated into three subfractions: VLDL-I, Sf 100-400 (Sf = Svedberg units); VLDL-II, Sf 60-100; VLDL-III, Sf 20-60. Rates of receptor-mediated degradation of VLDL-I and VLDL-II isolated from diabetic patients were significantly greater than the comparable subfraction isolated from control subjects and averaged 1023 +_ 279 vs 361 _+ 122 (p < 0.01) and 433 + 70 vs 294 + 70 ng. mg cell protein-'. 16 h -1 (p < 0.03), respectively. Rates of receptor-mediated degradation of the V-III subfraction isolated from the two groups did not differ significantly. There were no significant differences in the chemical composition or in the plasma concentrations of the VLDL subfractions isolated from diabetic patients compared to control subjects. There was a significant increase in the apoprotein E content of VLDL-I (p < 0.01) and VLDL-II (p < 0.05) isolated from diabetic patients. There was a significant increase in the ratio of apoprotein C compared to apoprotein E (p < 0.03) in VLDL-I isolated from control subjects compared to the diabetic patients. There were no significant differences in the apoprotein composition of VLDL-III isolated from the two groups.
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There is an increased prevalence of atherosclerosis in patients with diabetes mellitus and vascular disease accounts for 70 to 80 % of the deaths in diabetic patients [1] [2] [3] . Abnormalities of lipoprotein metabolism are intimately related to the development of atherosclerosis, and several abnormalities of lipoprotein metabolism have been described in diabetic patients. Most of these abnormalities have been described using cultured fibroblasts [4] [5] [6] or macrophages [7] [8] [9] [10] [11] . The endothelium of the arterial wall, however, plays an integral role in the maintenance of intravascular homeostasis and, therefore, in the development of atherosclerosis. Studies of lipoprotein interaction with endothelial cMls are limited, however, particularly as they relate to diabetes.
Lipoproteins interact with endothelial cells like other peripheral cell types studied in culture by binding, internalization and degradation via receptor-mediated pathways [12] [13] [14] [15] . Previous studies have shown that modifications of plasma lipoproteins due to the diabetic state alter the interaction of the lipoproteins with cell lipoprotein receptors.
The hyperglycaemia associated with diabetes results in the non-enzymatic glycation of apoproteins in LDL [16] and VLDL [17] . We have shown that glycation of LDL in vitro [7] or ofapoproteinB ofLDLisolated fromType 1 (insulindependent) [8] or Type 2 (non-insulin-dependent) [10] diabetic patients, alters its interaction with macrophage lipoprotein receptors. VLDL isolated from diabetic patients also exhibit altered chemical compositions [9] [10] [11] and this may contribute to their abnormal interaction with cell lipoprotein receptors. Recent studies have shown that the alterations in the chemical composition of VLDL are influenced by the level of glycaemic control and are specific for the size of the VLDL [18] .
Thus, we investigated if VLDL isolated from Type 1 diabetic patients would interact abnormally with human endothelial cells and if the abnormal interaction was associated with an altered composition of the VLDL. Furthermore, we investigated if the abnormal interaction and altered VLDL composition were specific for the size of the VLDL. "Values shown are mean + SEM and (range) for each population. u There was only one subject with BMI greater than 26 kg/m 2. This subject was normolipaemic and had only 9.5 % of body weight contributed by fat 
Subjects and methods

Subjects
Eleven patients with Type I diabetes with diagnoses based on the criteria established by the National Diabetes Data Group [19] and confirmed by plasma C-peptide levels of less than 0.5 ng/ml were recruited from the Private Diagnostic Clinic of the Medical University of South Carolina for this study. For every diabetic patient, an age-, sex-, and race-matched, non-diabetic control subject was recruited and blood was drawn on the same day from each member of the matched pair. Only normolipidaemic subjects were included in the study in order to exclude the potentially confounding effects of hypertriglyceridaemia on cell-lipoprotein interactions. Informed consent, as approved by the Institutional Review Board for Human Research of the Medical University of South Carolina, was obtained from each subject involved in the study.
None of the patients had proteinuria or other evidence of renal impairment. One patient had background retinopathy. No patient reported taking any medication except insulin. Additional clinical _characteristics of the diabetic and control groups are shown in Table 1 . Fasting plasma glucose, haemoglobin Aic (HbAI~) and fasting lipid profile were determined for all subjects and these data are shown in Table 2 . HbA~0 levels (p < 0.001) and fasting plasma glucose levels (p < 0.0]) were significantly higher in the diabetic patients. There were no significant differences in any of the parameters of the lipid profile between control subjects and diabetic patients.
Protocol
A 450 ml blood sample was collected from each subject after a 12-14 li fast. This sample was used to isolate discrete subfractions of VLDL for metabolic studies and for the determination of VLDL subfraction composition. VLDL subfractions from each subject were radiolabelled with 125I, and the degradation of lzsI-VLDL apoproteins by human endothelial cells was determined. Human endothelial cells were isolated from umbilical veins. The endothelial cells used for each experiment were isolated from an individual donor. Different donors were used for different experiments. Matched VLDL samples from diabetic patients and control subjects were always studied in the same experiment and each VLDL sample was incubated in triplicate. The lipid composition (free and ester• cholesterol, triglycerides and phospholipids) and apoprotein composition were measured in each VLDL sample.
Endothelial cell isolation and culture
Human umbilical vein endothelial cells were isolated from umbilical cords obtained from the Medical University of South Carolina Delivery Room. Cords were obtained as soon as possible after normal vaginal delivery and were placed in ice-cold cord buffer (0.14 mol/1 NaC1, 0.004 mol/l KC1, 0.001 tool/1 NaPO~, pH 7.35). The umbilical vein in undamaged cord segments was identified, was cannutated with a 2.54 cm straight, ball-tipped rat intubation tube which was then secured in the cord. The cord was flushed with cold cord buffer to remove blood. The other end of the vein was cannulated with a similar feeding tube which had rubber tubing attached. The vein was then flushed with additional cord buffer through the second cannula. The vein was filled with enough warm 0.1% collagenase (type 1 from Clostrodium histolyticum, Sigma Chemical Co., St. Louis, Mo., USA) in cord buffer (approximately 10 rot) to slightly distend it and the rubber tubing was clamped. The cord was placed in a sterile vessel containing cord buffer at 37 ~ covered with sterile aluminum foil and incubated for 15 rain at 37 ~ After the incubation, the cord was gently kneaded two times up and down its length and the collagenase solution flushed out of the vein with 30 ml cord buffer into a sterile 50 ml conical, plastic centrifuge tube containing 10 mt of a solution of 50 % ((volume/volume,v/v)) bovine calf serum (Sigma Chemical Co.) and Iscove's modified Dulbecco's medium (IMDM) (Gibco, Grand Island, NY, USA). The isolated cells were pelleted by centrifugation for 5 rain at 250 x g and the supernatant decanted. The endothelial cell pellet was gently resuspended in an endothelial cell growth medium (growth medium) with the following composition: IMDM containing human serum (Whittaker MA Bioproducts, Walkersville, Md., USA) (10 %, v/v) previously heat inactivated by incubation at 56 ~ for 45 min, heat inactivated fetal bovine serum (10%, v/v) (Sigma Chemical Co.), 5 U/ml catalase, 4tool/1 glutamine, 1 ~tg/ml transferrin, 100 U/ml penicillin, 100 p_g/ml streptomycin, 2.5 gg/ml amphotericin B and 150 ~tg/ml endothelial cell growth supplement (Sigma Chemical Co.) and transferred to a T-25 culture flask with the growth surface previously coated with gelatin (1%, weight/volume (w/v), porcine skin, type II, 175 bloom). Cells were incubated at 37~ in a humidified atmosphere of 95/5% air/CO2 and the medium was removed and replenished with medium of the same composition every 2-3 days. Cells generally grew to confluence in 3-4 days and were subcultured at a 1:3 ratio. To subculture the cells, the culture was harvested with trypsin-EDTA (0.05%: 0.02 %) at 37 ~ Cells were used for experimentation only after 2-4 passages. The endothelial identity of the cells is confirmed by visual observation of the "cobblestone" growth pattern and the presence of factor VIII antigen [20] . All experiments were conducted 3 days after the culture reached confluence.
R. L. Klein and M. F. Lopes-Virella: VLDL subfractions and endotheiial cells in diabetes pooled and concentrated and an aliquot was subjected to the ultracentrifugation conditions described above for the isolation of VLDL subfractions. Lipoproteins floating as VLDL-I, VLDL-II and VLDL-III were pooled for subsequent analysis. We examined the apoprotein B/apoprotein E of the ultracentrifugally isolated lipoproteins and compared it to the triglyceride rich lipoproteins isolated by column chromatography. The mean apoprotein B/apoprotein E ratio was similar for lipoproteins isolated by both methods (data not shown) suggesting that there was no significant loss of apoprotein E during the isolation of the VLDL subfractions.
VLDL subfraction isolation and composition
Blood for the isolation of VLDL subfractions was collected in the presence of a lipoprotein preservative solution containing EDTA (0.1%, w/v), chloramphenicol (20gg/ml), gentamycin sulphate (50 gg/ml) and &amino-caproic acid (0.13 %, w/v) (final concentrations). After the blood cells were sedimented by low speed centrifugation, the following chemicals were added to plasma at the indicated final concentrations to retard proteolysis: phenylmethylsulphonylfluoride (PMSF, 20 gg/ml, Sigma Chemical Co.), D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK, 1 gmol/1, Calbiochem-Behring, La Jolla, Calif., USA), and aprotinin (1 gg/ml, Sigma Chemical Co.).
VLDL (density (d) < 1.006 g/ml) were isolated from plasma at 10 ~ by ultracentrifugation at 60,000 rev/min for 18 h in a 60 Ti rotor (Beckman Instruments Inc., Palo Alto, Calif. USA). The floating VLDL was removed after tube slicing and this VLDL solution was used for the isolation of VLDL subfractions. The following subfractions of VLDL were isolated by cumulative flotation ultracentrifugation (Beckman SW 41 rotor) exactly as described [21] : VLDL-I (V-I), Sf 100-400 (Sf = Svedberg units); VLDL-II (V-II), Sf 60-100; VLDL-III (V-III), Sf 20-60. The isolated VLDL subfractions were dialysed against 0.9 % NaC1, 0.01% EDTA (w/v), pH 7.4. Salt solutions used to adjust the solvent densities also contained 0.01% EDTA, pH 7.4. The lipoprotein preparations were sterilized by passage through a 0.2 gm filter (Gelman Sciences, Ann Arbor, Mich., USA) and stored at 4 ~ under a N2 atmosphere.
Aliquots of the isolated VLDL fractions were extracted with chloroform/methanol (2 : 1, v/v) [22] . The free and total cholesterol [23] , triglyceride [24] , phospholipid phosphorus [25] , and total protein [26] concentrations of the lipoprotein samples were determined as described previously [10] . Lipoprotein lipid oxidation was determined by quantitating the amount of thiobarbituric acid reducing substances in each sample [27] .
The apoprotein composition of VLDL was examined using quantitative immunoelectrophoresis and RIA. VLDL apoprotein B concentrations were determined using quantitative immtmoelectrophoresis, with LDL (1.03 < d < 1.05) as the standard [4] . We have standardized this assay through our participation in an international collaborative study initiated by the Centers for Disease Control (CDC) and sponsored by the Standardization Committee of the International Union of Immunological Societies (IUIS) [28, 29] . Our results compare well with those reported by other investigators with an average coefficient of variation for our assay of less than 5.9 %. VLDL apoprotein E concentrations were kindly determined by Dr. T. Cole (Lipid Research Center, Washington University School of Medicine, St. Louis, Mo., USA) by RIA [30] . The average coefficient of variation for this assay is less than 6.1%. The concentration of apoprotein C was calculated as the difference between the total protein concentration of VLDL (apoproteins B, E and C) minus the sum of the concentrations of apoprotein B plus apoprotein E.
To determine if isolation of the individual VLDL subfractions by ultracentrifugation resulted in modifications of the apoprotein composition of the fractions, especially through loss of apoprotein E, the following studies were conducted. The triglyceride rich lipoprotein fraction was isolated by agarose column chromatography [31] of whole plasma obtained from two fasting, diabetic patients and two fasting, control subjects. Lipoproteins eluting in peak one were
VLDL accumulation and degradation studies
Aliquots of total VLDL or each VLDL subfraction isolated from each diabetic patient and control subject were radiolabelled with 125I as described previously [9] . To conduct an experiment, endothelial cells were grown to confluence in 24-well cluster culture plates. Three days later, the growth medium was removed and each culture was washed with i ml IMDM medium and 1 ml of growth medium without serum but containing 0.15 % (w/v) bovine serum albumin (Sigma Chemical Co.) was then added to each culture. ~25I radiolabelled total VLDL or VLDL subfractions (10 gg/ml) with or without non-radiolabelled total VLDL (250 gg/ml) isolated from the same subject was added to the medium and the cultures were incubated at 37 ~ for 16 h. The proteolytic degradation of t25I-VLDL by human endothelial cells was measured by assaying the amount of 125I-trichloroacetic-soluble (non-iodide) material formed by the cells and excreted into the culture medium as described previously [9] . Rates of total degradation were determined in incubations containing only ~2sI-VLDL and the rates of non-specific degradation were determined in parallel incubations containing a 25-fold excess of non-radiolabelled, total VLDL. Receptor-mediated degradation rates were calculated as the difference between total and non-specific degradation rates. The intracellular accumulation of 125I-VLDL was determined after removing the medium and washing the cultures. The cells were then dissolved in 1 ml of 0.2 mol/1 NaOH and the amount of ~25I radioactivity associated with the cells was determined. An aliquot of the solubilized cells was taken from each well for determination of cellular protein content as described previously [91.
Other methods
Plasma glucose was assayed by the glucose oxidase method, as adapted for use in the Beckman glucose analyser [32] . HbAlc was measured by cation exchange chromatography of erythrocyte haemolysates (Hemoglobin Ale Micro Column Test. Bio-Rad Laboratories, Hercules, Calif, USA). C-peptide levels in plasma were determined using a double-antibody RIA (C-Peptide; Diagnostic Products Corporation, Los Angeles, Calif., USA). Plasma HDL cholesterol concentration was determined after precipitating VLDL and LDL with sodium phosphotungstate/magnesium chloride as described previously [33] . Total cholesterol in whole plasma and lipoprotein fractions was measured using a continuous-flow analyzer (AutoAnalyzer I; Technicon Instruments, Tarrytown, NY, USA) with the chemically based Liebermann-Burchard method of analysis standardized by the Lipid Research Clinics Program [24] in their Manual of Laboratory Operations. Triglycerides in these fractions were assayed using a semi-automated, enzymatic method (Triglyceride Stat-Pak; Calbiochem-Behring) outlined in the same manual [24] .
Statistical analysis
Data from paired observations was analysed with the Wilcoxon signed-rank test. These analyses were determined with the Instat software program (GraphPad, San Diego, Calif., USA). 
Results
We investigated the interaction of VLDL with endothelial cell lipoprotein receptors by determining the rates of degradation of 12sI-VLDL isolated from the diabetic patients and control subjects. When the total VLDL (d < 1.006 g/ml) fraction was incubated with endothelial cells, the rate of receptor-mediated degradation by endothelial cells was significantly greater (p < 0.02) for VLDL isolated from diabetic patients compared to control subjects and averaged 1008 +_ 300 and 717 + 150 ng.mg cell protein -I. 16 h-~, respectively. Ra~es of non-specific degradation of the total VLDL fraction by endothelial cells did not differ significantly-and averaged 741 + 150 and 549 + 100 ng-mg cell protein-l. 16 h-1, respectively. The rate of receptormediated accumulation by endothelial cells of the total VLDL fraction was also significantly greater (p < 0.05) for VLDL isolated from diabetic patients compared with control subjects and averaged 1097 + 250 and 677 + 150 ng.mg cell protein-1.16 h-1, respectively. Rates of non-specific accumulation of the total VLDL fraction by endothelial cells also did not differ significantly and averaged 182 _+ 67 and 210 + 72 ng. mg cell protein-~. 16 h-1, for diabetic patients and control subjects, respectively.
To determine if the increase in the rates of receptormediated degradation by endothelial cells of VLDL isolated from diabetic patients was confined to particles of a specific size, we separated the total VLDL fraction from each subject into three discretely sized populations based on the rate of flotation of the particle in a salt gradient. There was a significant increase in the rates of receptormediated degradation ofV-I (p < 0.01) and V-II (p < 0.03) isolated from diabetic patients as shown by the data in Table 3 . Rates of receptor-mediated degradation of the V-III subfraction isolated from the two groups did not differ significantly and are also shown in Table 3 . There was also a significant increase in the rate of receptor-mediated accumulation ofV-I (p < 0.01) and V-II (p < 0.05) isolated from diabetic patients compared to control subjects and these results are detailed in Table 3 . Rates of accumulation of the V-III subfraction isolated from the two groups did not differ significantly.
To determine if the increased rates of degradation of VLDL-I and VLDL-II isolated from diabetic patients were associated with changes in the chemical composition of the subfraction, we analysed the lipid and protein composition of each VLDL subfraction. The chemical compositions of the VLDL subfractions isolated from the diabetic patients and control subjects are shown in Table 4 . There were no significant differences in the chemical composition of the V-I, V-II and V-III subfractions isolated from diabetic patients compared to control subjects. There were also no sig- a Mean + SEM; b p < 0.01, c p < 0.03 VS V-I fraction of diabetic group; d p < 0.05 vs V-II fraction of diabetic group nificant differences in the plasma concentrations of the three sub fractions in diabetic patients compared to control subjects as shown in Table 4 . We also analysed the extent of oxidation of the subfraction lipids by determining the amount of thiobarbituric acid reacting substances in the VLDL subfractions isolated from each subject. There were no significant differences in the amounts of thiobarbituric acid reacting substances in the subfractions isolated from diabetic patients compared to control subjects and these levels averaged 0. The apoprotein composition of the three subfractions was also analysed and these results are shown in Table 5 . The V-I subfraction isolated from diabetic patients was enriched in apoprotein E as shown by the significant decrease in the apoprotein B/apoprotein E ratio (p < 0.01). There was also a significant increase in the apoprotein C/apoprotein E ratio (p < 0.03) in the V-I fraction isolated from control subjects compared to the diabetic patients. Similarly, there was a significant increase in the apoprotein B/apoprotein E ratio (p < 0.05) in the V-II subfraction isolated from diabetic patients. There was no increase in the apoprotein C/apoprotein E ratio in the V-II fraction isolated from control subjects compared to the diabetic patients. There were no significant differences in the apoprotein composition of the V-Ill subfraction isolated from diabetic patients compared to control subjects.
Discussion
The results of the present study suggest that the metabolic behaviour of VLDL is significantly altered in Type 1 diabetic patients. Human endothelial cells degraded and accumulated significantly more VLDL isolated from Type I diabetic patients compared with VLDL isolated from matched control subjects. Furthermore, the increased degradation was specific for the larger sized VLDL particles. This suggests the presence of an alteration in lipoprotein metabolism in Type 1 diabetic patients, even in patients who are in fair to good glycaemic control and whose plasma lipid and lipoprotein levels are normal.
The observed increases in the rates of degradation and accumulation by endothelial cells of the large sized V-I and V-II subfractions isolated from diabetic patients were not associated with changes in the chemical composition of the VLDL subfractions. We [9] and others [34] have previously reported an increase in the free cholesterol content of the total VLDL fraction isolated from Type 1 diabetic patients. We have shown that the free cholesterol content of VLDL isolated from Type 1 diabetic patients decreases with improved levels of glycaemic control [35] . The free cholesterol content of the V-I subfraction isolated from a group of poorly-controlled Type 1 diabetic patients both before and after glycaemic controlwas attainedwas significantly greater than that in the V-I subfraction isolated from non-diabetic, control subjects [18] . The cause of the apparent discrepancy between the results of the present study and those of these previous studies is not readily apparent. However, because VLDL free cholesterol content is assodated with the level of glycaemic control and because the patients in the present study demonstrated much better levels of glycaemic controlthan did those in these previous studies, the level of glycaemic control in this population of diabetic patients may be a contributing factor.
We also analysed the apoprotein composition of the VLDL subfractions to identify factors responsible for the increased degradation by endothelial cells of the subfractions isolated from the diabetic patients. The V-I and V-II subfractions isolated from the diabetic patients were significantly enriched in apoprotein E. It has been shown repeatedly that apoprotein E molecules on VLDL serve as a ligand for the interaction of the particle with cell receptors [36] [37] [38] . Recent studies have shown that the enrichment of normal VLDL with apoprotein E significantly increases the catabolism of the VLDL by fibroblasts [39] and by macrophages [39, 40] . Thus, the increased apoprotein E content of V-I and V-II isolated from the diabetic patients may have resulted in increased recognition of the particles by endothelial cell lipoprotein receptors and thereby stimulated the catabolism of these large sized VLDL particles. In addition, previous studies have shown that VLDL isolated from fasting hypertriglyceridaemic subjects are degraded more rapidly than VLDL isolated from fasting subjects with normal triglyceride levels [36] . Additional studies showed that it is a unique orientation of apoprotein E on the surface of V-I isolated from hypertriglyceridaemic patients which mediates the uptake of the large V-I particles [41] and that the determinants for the binding of these VLDL to the LDL receptor switch from apoprotein E for V-I sized particles to apoprotein B for V-III sized particles [42] . The diabetic state may modify the apoprotein E molecules on the surface of V-I and V-II making the conformaReferences tion of apoprotein E on the VLDL subfractions isolated from diabetic patients more similar to those isolated from 1. hypertriglyceridaemicpatients. More of the lysine residues of apoprotein E in VLDL isolated from diabetic patients 2. are glycated than those from non-diabetic patients [17] . Individual epitopes of apoprotein E can be modulated, perhaps by glycation, and differences in apoprotein E confor-3. mation may significantly influence the metabolism of the lipoprotein [43, 44] . Thus, glycation of VLDL apoproteins, especially apoprotein E in large sized VLDL particles whose receptor binding determinant is apoprotein E, may alter the interaction of the lipoprotein with cell receptors.
The phenotype of apoprotein E on VLDL may influence its interaction with lipoprotein receptors. Unfortunately, sufficient material was not available for analysis of apoprotein E phenotype after the extensive analyses of lipoprotein composition and metabolism were completed. However, recent studies have shown the phenotype of apoprotein E from Type i and Type 2 diabetic patients to be similar to that of non-diabetic subjects [45] [46] [47] . In addition, the apoprotein E allele distribution is similar in diabetic patients and control subjects [48] . Therefore, the apoprotein E phenotype of VLDL isolated from the diabetic patients inthe present study presumably did not influence the interaction of the particles with endothelial cell lipoprotein receptors.
The contribution of this altered interaction between the V-I subfraction and endothelial cells to atherogenesis in diabetes remains to be demonstrated. However, alterations in the capacity of vascular endothelium to release either tissue plasminogen activator or plasminogen activator inhibitor-1 play an important role in the occurrence of thrombosis. Recent evidence suggests that VLDL may alter the secretion of these two critical proteins. The secretion of plasminogen activator inhibitor-1 has been shown to be induced by VLDL [49] . Furthermore, this enhanced secretion is dependent on the binding of VLDL to the na-11. tire LDL receptor. In addition, VLDL isolated from normal, but not hypertriglyceridaemic patients, stimulate the release of tissue plasminogen activator from endothelial cells and this stimulus is localized to the large sized VLDL 12. particles [50] . The effect of VLDL with altered apoprotein composition and with apoproteins modified by glycation on the release by endothelial cells of these proteins which 13. regulate fibrinolysis remains to be demonstrated.
In conclusion, we have shown that VLDL, especially the large sized particles, isolated from Type i diabetic pa-263 tients interact abnormally with human endothelial cells. Furthermore, this altered interaction was observed with VLDL isolated from patients in good to fair glycaemic control. The effect of this altered cell-lipoprotein interaction on endothelial cell metabolism and its role in the pathogenesis of atherosclerosis in diabetes remain to be determined. binding, internalization, and degradation by cultured human fibroblasts of low density lipoproteins isolated from type I (insulin-dependent) diabetic patients: changes with metabolic control. 
